Effects of anticancer agents on cell viability, proliferative activity and cytokine production of peripheral blood mononuclear cells

Journal of Clinical Biochemistry and Nutrition

Volumn 52, Issue 1, 2013, Pages 64-71

  Sakai, Hiromi ^a   Kokura, Satoshi ^a   Ishikawa, Takeshi ^a   Tsuchiya, Reiko ^a   Okajima, Manabu ^a   Matsuyama, Tatsuzou ^a   Adachi, Satoko ^a   Katada, Kazuhiro ^a   Kamada, Kazuhiro ^a   Uchiyama, Kazuhiko ^a   Handa, Osamu ^a   Takagi, Tomohisa ^a   Yagi, Nobuaki ^a   Naito, Yuji ^a   Yoshikawa, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

5 fluorouracil (5 FU); Chemoimmunotherapy; Cisplatin (CDDP); Gemcitabine (GEM); Irinotecan (CPT 11)

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; GEMCITABINE; INTERFERON; IRINOTECAN; PHYTOHEMAGGLUTININ;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE;

EID: 84872354127     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.12-60     Document Type: Article

References (25)

1. AbdAlla EE, Blair GE, Jones RA, Sue-Ling HM, Johnston D. Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line. J Natl Cancer Inst 1995; 87: 489-496.
2. Bergmann-Leitner ES, Abrams SI. Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol Immunother 2001; 50: 445-455. (Pubitemid 33079340)
3. Correale P, Del Vecchio MT, La Place M, et al. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. J Immunother 2008; 31: 132-147.
4. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Crosstalk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179: 977-983.
5. Hirooka Y, Ito A, Kawashima H, et al. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. Pancreas 2009; 38: e69-e74.
6. Suzuki E, Sun J, Kapoor V, Jassar AS, Albelda SM. Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects. Cancer Biol Ther 2007; 6: 880-885. (Pubitemid 351574977)
7. Prete SP, Turriziani M, Massara MC, et al. Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy. J Exp Clin Cancer Res 2008; 27: 5.
8. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8(1): 59-73.
9. Correale P, Cusi MG, Micheli L, et al. Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience. Invest New Drugs 2006; 24: 99-110. (Pubitemid 43738963)
10. Alvino E, Fuggetta MP, Tricarico M, Bonmassar E. 2′-2′- difluorodeoxycytidine: in vitro effects on cell-mediated immune response. Anticancer Res 1998; 18: 3597-3602. (Pubitemid 28546496)
11. Tiefenthaler M, Hohla F, Irschick E, et al. In vitro studies on the immunosuppressive effect of 2′,2′-difluorodeoxycytidine (dFdC) and its metabolite 2′,2′-difluorodeoxyuridine (dFdU). Immunobiology 2003; 207: 149-157. (Pubitemid 36367388)
12. Margreiter R, Fischer M, Roberts K, et al. Gemcitabine - a novel immunosuppressive agent - prevents rejection in a rat cardiac transplantation model. Transplantation 1999; 68: 1051-1053. (Pubitemid 29489334)
13. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effects on the humoral immune response: implications for combination chemoimmunothrapy. Cancer Res 2002; 62: 2353-2358. (Pubitemid 34411717)
14. Agarwal A, Verma S, Burra U, Murthy NS, Mohanty NK, Sexana S. Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder. Cancer Immunol Immunother 2006; 55: 734-743.
15. Hadden JW. Recent advances in the preclinical and clinical immunopharmacology of interleukin-2: emphasis on IL-2 as an immunorestrative agent. Cancer Detect Prev 1988; 12: 537-552.
16. Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009; 9: 900-909.
17. Plate JM, Plate AE, Shott S, Bograd S, Harris JE. Effects of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 2005; 54: 915-925. (Pubitemid 40991334)
18. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11: 6713-6721. (Pubitemid 41339014)
19. de Rezende, Silva IV, Rangel LB, Guimaraes MC. Regulatory T cells as a target for cancer therapy. Arch Immunol Ther Exp (Warsz) 2010; 58: 179-190.
20. Nicholl M, Lodge A, Brown I, Sugg SL, Shilyansky J. Restored immune response to an MHC-II-Restricted antigen in tumor-bearing hosts after elimination of regulatory T cells. J Pediatr Surg 2004; 39: 941-946. (Pubitemid 38833787)
21. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 2005; 54: 369-377. (Pubitemid 41748714)
22. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115: 3623-3633. (Pubitemid 43121851)
23. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 5211-5218.
24. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59: 3128-3133. (Pubitemid 29316012)
25. Kimura Y, Tsukada J, Tomoda T, et al. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas 2012; 41: 195-205.